NorthShore Bio

About:

NorthShore Bio (NSB) is developing a silicon-chip Molecular Detection Platform.

Website: http://northshorebio.com

Top Investors: Keiretsu Forum Northwest

Description:

NorthShore Bio (NSB) is developing a silicon-chip Molecular Detection Platform based on a proprietary, hybrid nanopore technology that combines solid-state, tunable nanopores with direct single molecule detection and integrated digital output. The initial focus is on direct RNA sequencing, and "next" generation DNA sequencing with major advances in read length, resolution, data analytics, and speed. NSB's new generation of molecular detection platform draws on methods harnessed from the silicon microchip industry. As the technology advances, it is expected to enable sequencing read lengths of >50,000bp, enabling sequencing of a whole human genome in less than 5 hours and at a cost of less than $500. NSB's chip platform also scales nicely into diagnostics applications, potentially enabling multiplexed assays at a fraction of their current cost. While still in development, NSB has successfully conquered several key hurdles on the way to a Proof of Concept, including demonstrating label-free single molecule detection (of DNA base transits).

Total Funding Amount:

$1.48M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Camas, Washington, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)northshorebio.com

Founders:

Gordon Holt

Number of Employees:

11-50

Last Funding Date:

2015-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai